Simplified Endoscopic Score for Crohn's Disease (SES-CD)
Endoscopic scoring of Crohn's disease activity across 5 ileocolonic segments. Correlates with CDAI and is used as an endpoint in clinical trials.
Score interpretation
SES-CD 0–2 — endoscopic remission or inactive disease
→ Maintain therapy; standard follow-up
SES-CD 3–6 — mild endoscopic activity
→ Consider intensification; optimise current treatment
SES-CD 7–15 — moderate endoscopic activity
→ Biologic therapy or combination immunosuppression; re-scope at 3–6 months
SES-CD >15 — severe endoscopic activity
→ Urgent intensification; surgical consultation; biologic rescue therapy
Interpretation bands for the SES-CD. Apply clinical judgement and local guidance.
References
- Daperno M et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc. 2004;60(4):505–512.
Related
Curated clinical cross-links plus same-class fallbacks.
- Harvey-Bradshaw Index for Crohn's Disease · Inflammatory Bowel Disease
- Mayo Score for Ulcerative Colitis Activity · Inflammatory Bowel Disease
- Crohn's Disease Activity Index (CDAI) · Inflammatory Bowel Disease
- Truelove and Witts Severity Index for Ulcerative Colitis · Inflammatory Bowel Disease
- Ulcerative Colitis Endoscopic Index of Severity (UCEIS) · Inflammatory Bowel Disease
- Travis Criteria for Severe Ulcerative Colitis · Inflammatory Bowel Disease
- Dapsone · Anti-inflammatory / Antimicrobial
- Methotrexate (Dermatology — Psoriasis) · Disease-Modifying Antirheumatic / Immunosuppressant
- Risankizumab · IL-23 Inhibitor — Psoriasis / Crohn's
- Colchicine · Anti-inflammatory — Neutrophilic Dermatoses / Vasculitis
- Birch bark extracts (betulin) · Topical wound healing agent
- Acetazolamide (Ménière's Disease) · Carbonic Anhydrase Inhibitor (Diuretic)
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.